Record Earnings and Dividends
Integral Diagnostics Reports Strong Revenue Growth and Increased Dividends Following Successful Merger Integration
Anonymous
Key Points
1
IDX added three new directors to its board—Mr Fay, Ms Player, and Mr Hall—bringing extensive governance, financial, and healthcare leadership experience; the board structure includes roles such as Chair of the People, Culture Committee (Mr Fay) and Chair of the Risk, Compliance and Sustainability Committee (Ms Player).
2
Analysts at TipRanks designate Integral Diagnostics as a Buy, with a targeted price of A$3.20, signaling positive near-term sentiment despite ongoing merger integration.
3
Organic revenue growth in FY26 shows Australia delivering 7.4% growth (8.9% for legacy IDX, 5.4% for Capitol), New Zealand growing 2.1% (all figures on a constant currency basis), with average fees per exam in Australia up 6.5%.
4
MERGER synergies exceeded targets, with ongoing synergies surpassing $14.0m for Capitol Health integration; the company also highlighted National Lung Cancer Screening Program activity, accounting for about 14% of national lung cancer screenings.
5
The group held cash of about $51.3m and has committed facilities of $467.4m, with $117.0m undrawn, providing liquidity to support ongoing expansion and capex initiatives.
Integral Diagnostics reported strong results for fiscal year 2026, with revenue climbing 25.6% to AUD 788.7 million and operating profit jumping about 50% to AUD 47.4 million Grafa. The Australian diagnostic imaging company declared a fully franked final dividend of 6.0 cents per share, marking a 50% increase and reflecting confidence in its merger integration and growth prospects Kalkine.
The strong performance came from patient volume growth, Medicare indexation, and successful integration of the Capitol Health merger. Operating EBITDA jumped 30.3% to AUD 164.8 million, while operating free cash flow reached AUD 106.4 million, supporting a balance sheet with debt at about 2.3x leverage Market Screener. Analysts at TipRanks rated the stock a Buy with a target price of A$3.20.
Capitol Health Merger Synergies Beat Targets
Integral Diagnostics extracted more than AUD 14 million in merger synergies during FY26, exceeding internal targets Grafa. The Capitol Health acquisition, which closed last year, contributed AUD 5.4% organic revenue growth, while the legacy IDX business delivered 8.9% growth in Australia. New Zealand operations grew 2.1% on a constant currency basis.
Average fees per exam in Australia climbed 6.5%, benefiting from higher-value imaging modalities and improved pricing power Kalkine. The National Lung Cancer Screening Program accounted for about 14% of national lung cancer screenings, demonstrating the company's growing role in preventive care.
Board Expansion Brings Healthcare and Financial Expertise
Integral Diagnostics added three new directors to strengthen governance and strategic oversight Market Screener. Mr Fay took the chair of the People and Culture Committee, while Ms Player leads the Risk, Compliance and Sustainability Committee. Mr Hall brought additional financial and healthcare leadership experience to the board.
The expanded board reflects the company's growth phase and integration of Capitol Health. The new directors bring expertise in healthcare operations, financial management, and risk oversight. This restructuring supports Integral's plan to expand margins above 21% in coming years.
Strong Cash Position Funds Expansion and Growth
Integral Diagnostics held AUD 51.3 million in cash and has access to AUD 467.4 million in committed credit facilities, with AUD 117 million undrawn Market Screener. This liquidity cushion enables the company to fund capital expenditure, pursue selective network expansion, and support ongoing integration activities.
The company plans to expand its imaging footprint with new sites while investing in digital innovation, including its IDXt teleradiology platform Kalkine. Management flagged disciplined core growth and margin expansion as key priorities, targeting organic growth alongside operational efficiency gains.
Earnings Jump Driven by Volume and Pricing Power
Operating NPAT surged 50.1% to AUD 47.4 million as patient volumes rose and Medicare indexation lifted fees Kalkine. Operating EBITDA climbed 30.3% to AUD 164.8 million, delivering a 20.9% margin. This strong profitability growth outpaced revenue expansion, showing improved operational leverage.
Operating free cash flow of AUD 106.4 million demonstrates the cash-generative nature of the diagnostic imaging business Market Screener. The company's leverage sits at approximately 2.3x, providing headroom for future capital allocation while maintaining financial flexibility.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
7
Reach
17
A
AnonymousAuthor
